Inflammation in pulmonary hypertension: What we know and what we could logically and safely target first

Drug Discovery Today

Volumn 19, Issue 8, 2014, Pages 1251-1256

  Cohen Kaminsky, Sylvia ^a,b,c   Hautefort, Aurélie ^a,b,c   Price, Laura ^e   Humbert, Marc ^a,b,c,d   Perros, Frédéric ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b Universite Paris Sud   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d BICÊTRE HOSPITAL   (France)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; ANTIINFLAMMATORY AGENT; BERAPROST; BOSENTAN; CD20 ANTIBODY; CYCLOSPORIN; DEXAMETHASONE; ETANERCEPT; GLUCOCORTICOID; ILOPROST; INTERLEUKIN 6 RECEPTOR; MACITENTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROSTACYCLIN; RIOCIGUAT; RITUXIMAB; SILDENAFIL; TADALAFIL; TREPROSTINIL; IMMUNOLOGIC FACTOR;

ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; GENE OVEREXPRESSION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLAMMATION; NONHUMAN; PROTEIN TARGETING; PULMONARY HYPERTENSION; REVIEW; VASCULAR LESION; ANIMAL; IMMUNOLOGY;

ANIMALS; AUTOIMMUNITY; HUMANS; HYPERTENSION, PULMONARY; IMMUNOLOGIC FACTORS; INFLAMMATION;

EID: 84906316920     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.04.007     Document Type: Review

References (81)

1. M. Humbert et al. Treatment of pulmonary arterial hypertension N. Engl. J. Med. 351 2004 1425 1436
2. Y. Wu et al. An update on medical therapy for pulmonary arterial hypertension Curr. Hypertens. Rep. 15 2013 614 622
3. F. Perros et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension Am. J. Respir. Crit. Care Med. 185 2012 311 321
4. N. Kherbeck et al. The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension Clin. Rev. Allergy Immunol. 44 2013 31 38
5. L.C. Price et al. Inflammation in pulmonary arterial hypertension Chest 141 2012 210 221
6. F. Perros et al. Novel immunopathological approaches to pulmonary arterial hypertension Presse Méd. 40 Suppl. 1 2011 3 13 (in French)
7. N.F. Voelkel et al. Pathobiology of pulmonary arterial hypertension and right ventricular failure Eur. Respir. J. 40 2012 1555 1565
8. J. Meloche et al. Anti-inflammatory and immunosuppressive agents in PAH Handb. Exp. Pharmacol. 218 2013 437 476
9. D. Montani et al. Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease Eur. Respir. J. 26 2005 969 972
10. O. Sanchez et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension Chest 130 2006 182 189
11. X. Jais et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases Arthritis Rheum. 58 2008 521 531
12. M. Idzko et al. Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function J. Clin. Invest. 117 2007 464 472
13. Z. Jaffar et al. Prostaglandin I2-IP signaling blocks allergic pulmonary inflammation by preventing recruitment of CD4+ Th2 cells into the airways in a mouse model of asthma J. Immunol. 179 2007 6193 6203
14. W. Zhou et al. Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells J. Immunol. 178 2007 702 710
15. B. Raychaudhuri et al. The prostacyclin analogue treprostinil blocks NFkappaB nuclear translocation in human alveolar macrophages J. Biol. Chem. 277 2002 33344 33348
16. E.M. Zardi et al. Endothelial dysfunction and activation as an expression of disease: role of prostacyclin analogs Int. Immunopharmacol. 5 2005 437 459
17. K. Goya et al. Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus Metabolism 52 2003 192 198
18. H. Katsushi et al. Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension Circ. J. Off. J. Jpn. Circ. Soc. 68 2004 227 231
19. M. Fartoukh et al. Chemokine macrophage inflammatory protein-1alpha mRNA expression in lung biopsy specimens of primary pulmonary hypertension Chest 114 Suppl. 1 1998 50 51
20. J.K. Damås et al. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells Circulation 110 2004 999 1005
21. F. Rose et al. Increased neutrophil mediator release in patients with pulmonary hypertension - suppression by inhaled iloprost Thromb. Haemost. 90 2003 1141 1149
22. M-K. Tsai et al. Effect of prostaglandin I2 analogs on macrophage inflammatory protein 1α in human monocytes via I prostanoid receptor and cyclic adenosine monophosphate J. Investig. Med. 62 2014 332 339
23. S. Hall et al. Contribution of inflammation to the pathology of idiopathic pulmonary arterial hypertension in children Thorax 64 2009 778 783
24. R. Friedman et al. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension Circulation 96 1997 2782 2784
25. M. Browatzki et al. Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells Basic Res. Cardiol. 95 2000 98 105
26. E. Helset et al. Endothelin-1 causes sequential trapping of platelets and neutrophils in pulmonary microcirculation in rats Am. J. Physiol. 271 1996 538 546
27. F. Finsnes et al. Endothelin production and effects of endothelin antagonism during experimental airway inflammation Am. J. Respir. Crit. Care Med. 155 1997 1404 1412
28. F. Finsnes et al. Effect of endothelin antagonism on the production of cytokines in eosinophilic airway inflammation Am. J. Physiol. Lung Cell Mol. Physiol. 280 2001 659 665
29. S. Verma et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein Circulation 105 2002 1890 1896
30. D. Uhlmann et al. Effects of ET(A) receptor antagonism on proinflammatory gene expression and microcirculation following hepatic ischemia/reperfusion Microcirc. 12 2005 405 419
31. E.F. Hauck et al. Endothelin A receptor antagonist BSF-208075 causes immune modulation and neuroprotection after stroke in gerbils Brain Res. 1157 2007 138 145
32. G. Guruli et al. Function and survival of dendritic cells depend on endothelin-1 and endothelin receptor autocrine loops Blood 104 2004 2107 2115
33. G.K. Karavolias et al. Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses Expert Opin. Ther. Targets 14 2010 1283 1289
34. W. Wang et al. Impairment of monocyte-derived dendritic cells in idiopathic pulmonary arterial hypertension J. Clin. Immunol. 29 2009 705 713
35. T.J. Toward et al. Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease Am. J. Respir. Crit. Care Med. 169 2004 227 234
36. P. Serafini et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function J. Exp. Med. 203 2006 2691 2702
37. S. Karakhanova et al. Gender-specific immunological effects of the phosphodiesterase 5 inhibitor sildenafil in healthy mice Mol. Immunol. 56 2013 649 659
38. P. Shenoy, and V. Agarwal Phosphodiesterase inhibitors in the management of autoimmune disease Autoimmun. Rev. 9 2010 511 515
39. L.C. Price et al. Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats Eur. Respir. J. 37 2011 813 822
40. A. Ogawa et al. Prednisolone ameliorates idiopathic pulmonary arterial hypertension Am. J. Respir. Crit. Care Med. 183 2011 139 140
41. S. Hennigan et al. Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report Lupus 17 2008 754 756
42. B. Terrier, and L. Mouthon Recombinant proteins or monoclonal antibodies: comparative properties and interest in systemic lupus erythematosus Méd. Sci. 29 2013 65 73 (in French)
43. G. Cartron, and J.-F. Rossi Therapeutic monoclonal antibodies in onco-hematology Méd. Sci. 25 2009 1085 1089 (in French)
44. L. Semerano, and M.-C. Boissier Monoclonal antibodies in chronic autoimmune inflammatory diseases Méd. Sci. 25 2009 1108 1112 (in French)
45. M.R. Nicolls et al. Autoimmunity and pulmonary hypertension: a perspective Eur. Respir. J. 26 2005 1110 1118
46. Y. Tanaka Diagnosis and therapy for systemic lupus erythematosus Nihon Naika Gakkai Zasshi J. Jpn. Soc. Intern. Med. 96 2007 2159 2164
47. P.P. Sfikakis et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial Arthritis Rheum. 52 2005 501 513
48. M. Rincon Interleukin-6: from an inflammatory marker to a target for inflammatory diseases Trends Immunol. 33 2012 571 577
49. T. Kishimoto Interleukin-6 and its receptor in autoimmunity J. Autoimmun. 5 Suppl. A 1992 123 132
50. M.K. Steiner et al. Interleukin-6 overexpression induces pulmonary hypertension Circ. Res. 104 2009 236 244
51. M. Humbert et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension Am. J. Respir. Crit. Care Med. 151 1995 1628 1631
52. G.A. Heresi et al. Plasma interleukin-6 adds prognostic information in pulmonary arterial hypertension Eur. Respir. J. 43 2014 912 914
53. J-L. Cracowski et al. Proinflammatory cytokine levels are linked with death in pulmonary arterial hypertension Eur. Respir. J. 43 2014 915 917
54. E. Soon et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension Circulation 122 2010 920 927
55. Y. Furuya et al. Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension Int. J. Rheumatol. 2010 2010 720305
56. Y. Arita et al. The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease Heart Vessels 25 2010 444 447
57. K. Taniguchi et al. Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease Int. J. Hematol. 90 2009 99 102
58. M.N. Gillespie et al. Interleukin 1 bioactivity in the lungs of rats with monocrotaline-induced pulmonary hypertension Proc. Soc. Exp. Biol. Med. 187 1988 26 32
59. B. Girerd et al. Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension Respir. Res. 11 2010 73
60. M.E. Pugh, and A.R. Hemnes Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease Womens Health 6 2010 285 296
61. E.K. Larkin et al. Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension Am. J. Respir. Crit. Care Med. 186 2012 892 896
62. E.D. Austin et al. T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension Respir. Med. 104 2010 454 462
63. S. Ulrich et al. Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension Respir. Int. Rev. Thorac. Dis. 75 2008 272 280
64. A. Huertas et al. Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension Eur. Respir. J. 40 2012 895 904
65. R. Savai et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension Am. J. Respir. Crit. Care Med. 186 2012 897 908
66. R. Tamosiuniene et al. Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension Circ. Res. 109 2011 867 879
67. F. Perros et al. Understanding the role of CD4+CD25(high) (so-called regulatory) T cells in idiopathic pulmonary arterial hypertension Respir. Int. Rev. Thorac. Dis. 75 2008 253 256
68. M.C. Tamby et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension Thorax 60 2005 765 772
69. B. Terrier et al. Antifibroblast antibodies from systemic sclerosis patients bind to {alpha}-enolase and are associated with interstitial lung disease Ann. Rheum. Dis. 69 2010 428 433
70. B. Terrier et al. Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension Am. J. Respir. Crit. Care Med. 177 2008 1128 1134
71. M. Karmochkine et al. High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension J. Rheumatol. 23 1996 286 290
72. P. Riboldi et al. Endothelium as a target for antiphospholipid antibodies Immunobiology 207 2003 29 36
73. G. Bussone et al. IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction Ann. Rheum. Dis. 71 2012 596 605
74. Y. Renaudineau et al. Antiendothelial cell antibodies in systemic lupus erythematosus Autoimmun. Rev. 1 2002 365 372
75. V.S. Negi et al. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension J. Rheumatol. 25 1998 462 466
76. S.J. Arends et al. Prevalence of anti-endothelial cell antibodies in idiopathic pulmonary arterial hypertension Eur. Respir. J. 35 2010 923 925
77. F.P. Quismorio Jr. et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus Semin. Arthritis Rheum. 13 1984 349 359
78. H. Dib et al. Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma Eur. Respir. J. 39 2012 1405 1414
79. K.L. Colvin et al. Bronchus-associated lymphoid tissue in pulmonary hypertension produces pathologic autoantibodies Am. J. Respir. Crit. Care Med. 188 2013 1126 1136
80. L. Taraseviciene-Stewart et al. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling Am. J. Respir. Crit. Care Med. 175 2007 1280 1289
81. S. Mizuno et al. Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization Am. J. Respir. Cell. Mol. Biol. 47 2012 679 687